Drawing for MOLECULAR HEALTH GUIDE

USPTO serial 87048013

MOLECULAR HEALTH GUIDE

Reviewed by CopyMark Law Group

Reg. 5510111Status 701Registered
Filing date
Status date
Registration date
Jul 3, 2018
Examiner
HISER, CHARLES
Law office
Historical data usage

What this means

Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary. Calendar the 10-year Section 8 and 9 combined renewal.

Status 701: Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary.

Need help with MOLECULAR HEALTH GUIDE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Peter T. Wakiyama

Peter T. Wakiyama Troutman Pepper Hamilton Sanders LLP3000 Two Logan SquareEighteenth and Arch StreetsPHILADELPHIA, PA 19103

Goods and services

ClassDescriptionStatusFirst use
009Downloadable computer databases containing information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology; downloadable computer databases containing medical and health information on humans; downloadable computer software for accessing, organizing, indexing, ranking, integrating, linking, referencing, synthesizing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humans; downloadable mobile applications for mobile devices, for accessing, organizing, synthesizing, indexing, ranking, integrating, linking, referencing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humans; downloadable mobile applications for accessing databases in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals and pharmaceutical safety, life sciences and biotechnologyACTIVEJun 3, 2016
038Providing access to searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information and records, molecular test results and patient specific data about or relating to humans for scientific research purposes; providing access to online databases containing medical, pharmaceutical, biological, clinical, molecular, sequencing and genomic information, disease information, biomarker information and medical or health information or records about or relating to humans and patient specific data, molecular test results, and scientific research for medical diagnostic and treatment purposes; providing access to online software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing access to non-downloadable computer software and algorithms for medical diagnostic and treatment purposesACTIVEJun 3, 2016
042Consulting and research services in the fields of health care, medicine, life sciences, biotechnology, pharmaceuticals, bioinformatics, genomics and pharmaceuticals and pharmaceutical safety for scientific research purposes; consulting and research services in the nature of retrieval, integration, correlation, analysis and interpretation of genomic, sequencing, and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, medical health information patient specific data, molecular test results, data from clinical studies, and scientific research for purposes of scientific, medical and pharmaceutical research; designing and developing searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information and records, molecular test results and patient specific data about or relating to humans for scientific research purposes; providing temporary use to non-downloadable computer software and algorithms for managing large amounts of genetic data, accessing genetic information in large databases in use by physicians, clinicians and other healthcare professionals, laboratory personnel, consultants, scientists and other researchers for purposes of scientific, medical and pharmaceutical research; providing temporary use to non-downloadable software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for purposes of scientific, medical and pharmaceutical research; providing temporary use to non-downloadable applications for mobile devices, namely, smart phones and tablets, and web applications accessible through the internet providing information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology for scientific research purposes; data collection services for scientific research purposes in the fields of genomics, health care, pharmaceuticals, life sciences, bioinformatics, biotechnology and medicine; services for mobile devices, namely, smart phones and tablets, being software design; non-downloadable web applications for accessing databases accessible through the internet in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals and pharmaceutical safety, life sciences and biotechnology; consulting in the fields of biotechnology, bioinformatics, life sciences; providing temporary use of non-downloadable computer software and algorithms for managing large amounts of genetic data, accessing genetic information in large databases for medical diagnostic and treatment purposes; medical research services, namely, the retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; consulting services in the fields of biotechnology, bioinformatics, and life sciences; Medical research services, namely, the retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposesACTIVEJun 3, 2016
044Medical consulting services, namely, the retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; consulting services in the fields of health, medical care, pharmaceuticals and medicine; providing medical information in the fields of health, healthcare, life sciences, biotechnology, pharmaceuticals and pharmaceutical safety, bioinformatics, and genetic testing for medical purposes; medical consulting services with respect to the treatment and diagnosis of individuals; providing medical information on drug safety and drug compatibility in relation to therapy and the treatment of individuals; medical consulting services in the fields of diagnostics and patient treatment and treatment protocolsACTIVEJun 3, 2016

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 8, 2025NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Apr 8, 20258.OKREGISTERED - SEC. 8 (6-YR) ACCEPTEDThe USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline.
Apr 7, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Sep 13, 2024ES8RTEAS SECTION 8 RECEIVED—
Jul 3, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jul 3, 2018R.SRREGISTERED-SUPPLEMENTAL REGISTERYour mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application.
May 31, 2018PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 24, 2018CNTAAPPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER—
May 16, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 16, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 11, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 11, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 14, 2017AAUANOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED—
Nov 11, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 11, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 11, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 11, 2017IUAAUSE AMENDMENT ACCEPTED—
Oct 23, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 23, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 10, 2017ALIEASSIGNED TO LIE—
Sep 28, 2017AUPCAMENDMENT TO USE PROCESSING COMPLETE—
Sep 28, 2017IUAFUSE AMENDMENT FILED—
Sep 27, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 27, 2017EAAUTEAS AMENDMENT OF USE RECEIVED—
Mar 27, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 16, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 15, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 15, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 15, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 15, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 15, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 8, 2016DOCKASSIGNED TO EXAMINER—
Jun 1, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 27, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance